ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Fighting Heartburn and Gerd Naturally – And Safely!

Natural Bladder Control, Go Less and Live More

Vital Molecule Increases Cellular Energy and Improves Cognitive Function

Top Vitamin and Mineral Deficiencies — Are You at Risk?

Trimming the spare tire: Canola oil may cut belly fat

How Pomegranate May Protect Against Cancer

Omega Fix for Obesity: How the Right Fats Fight Fat

The Onion: Cancer Fighter and Food Preserver

Probiotics improve cognition in Alzheimer's patients

Curcumin Reverses the Cellular Damage of Chronic Stress

 
Print Page
Email Article

Development of responder definitions for fibromyalgia clinical trials – Source: Arthritis & Rheumatism, Sep 27, 2011

  [ 6 votes ]   [ Discuss This Article ]
By Lesley M Arnold, et al. • www.ProHealth.com • September 30, 2011


Objective: To develop responder definitions for fibromyalgia clinical trials using key symptom and functional domains.

Methods:
24 candidate responder definitions were developed by expert consensus and evaluated in 12 randomized, placebo-controlled fibromyalgia trials of 4 medications.

For each definition, treatment effects of the medication compared with placebo were analyzed using the Cochran-Mantel-Haenszel test or Chi Square test.

A meta-analysis of the pooled results for the 4 medications established risk ratios to determine the definitions that best favored medication over placebo.

Results:

Two definitions performed best in the analyses.

Both definitions included 30% or greater reduction in pain and 10% or greater improvement in physical function.

They differed in that:

• One (FM30 short version) included 30% or greater improvement in sleep or fatigue,

• And the other (FM30 long version) required 30% or greater improvement in 2 of the following symptoms: sleep, fatigue, depression, anxiety, or cognition.

In the analysis of both versions, the response rate was 15% or greater for each medication and significantly greater than placebo.

The risk ratio favoring drug over placebo (95% CI) in the pooled analysis for the FM30 short version was 1.50 (1.24, 1.82), P 0.0001 or less; the FM30 long version was 1.60 (1.31, 1.96), P 0.00001 or less. [Note: a risk ratio of 1.0 would indicate no difference vs the placebo. RR’s of 1.50 and 1.60 would indicate a 50% greater response rate than placebo required with the FM30 short version and 60% greater response rate required with the FM30 long version, respectively.]

Conclusion:


Among the 24 responder definitions tested, 2 were identified as most sensitive in identifying response to treatment.

The identification of responder definitions for fibromyalgia clinical trials that include assessments of key symptom and functional domains may improve the sensitivity of clinical trials to identify meaningful improvements, leading to improved management of fibromyalgia.

Source:
Arthritis & Rheumatism, Sep 27, 2011. PMID: 21953205 by Arnold LM, Williams DA, Hudson JI, Martin SA, Clauw DJ, Crofford LJ, Wang F, Emir B, Lai C, Zablocki R, Mease PJ. University of Cincinnati College of Medicine, Cincinnati, Ohio; University of Michigan Medical School, Ann Arbor, Michigan;  Harvard Medical School/McLean Hospital, Belmont, Massachusetts; RTI-Health Solutions, Ann Arbor, Michigan; University of Kentucky, Lexington, Kentucky; Eli Lilly and Company, Indianapolis, Indiana; Pfizer, Inc., New York, New York; Jazz Pharmaceuticals, Inc., Palo Alto, California; Cypress Bioscience, Inc. San Diego, California; Swedish Medical Center, and University of Washington, Seattle, Washington, USA. [Email -
Lesley.Arnold@uc.edu]





Post a Comment

Featured Products From the ProHealth Store
Ultra EPA  - Fish Oil FibroSleep™ Mitochondria Ignite™ with NT Factor®


Article Comments



Be the first to comment on this article!

Post a Comment


 
Natural Pain Relief Supplements

Featured Products

Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid

Natural Remedies

Reversing Neurodegeneration with a New Magnesium Compound Reversing Neurodegeneration with a New Magnesium Compound
Relief for Dry, Itchy Skin Caused by Fibromyalgia Relief for Dry, Itchy Skin Caused by Fibromyalgia
Cell-Charging Compound Gives Steady Energy to Fibromyalgia & Chronic Fatigue Patients Cell-Charging Compound Gives Steady Energy to Fibromyalgia & Chronic Fatigue Patients
Natural Bladder Control, Go Less and Live More Natural Bladder Control, Go Less and Live More
The Crucial Role CoQ10 Plays in Fibromyalgia and ME/CFS The Crucial Role CoQ10 Plays in Fibromyalgia and ME/CFS

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map